PolyPid's Participation in a Notable Conference
PolyPid Ltd., a leading biopharmaceutical company, is committed to enhancing surgical outcomes with its innovative approaches. Recently, the company announced its participation in a vital conference, showcasing its advancements in the field.
Details of the Presentation
Dalit Hazan, the Deputy CEO and Executive Vice President of Research, Development, Clinical, and Regulatory Affairs, will represent the company. The presentation is scheduled for a prime slot on September 7 during the highly anticipated Session 1, focused on 'Advances in Targeted and Controlled Drug Delivery.'
Significance of the Presentation
During her talk, Hazan will unveil the topic titled 'Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial'. This presentation aims to provide insights into how PolyPid’s unique methods are changing the landscape of drug delivery in surgical environments.
About PolyPid Ltd.
Founded with the goal of improving surgical outcomes, PolyPid Ltd. leverages its proprietary PLEX technology, which combines Polymer-Lipid Encapsulation technology with Active Pharmaceutical Ingredients (APIs). This cutting-edge approach enables healthcare professionals to administer therapeutics that release drugs at tailored rates over extended periods, addressing significant clinical needs.
Innovative Pipeline
PolyPid is progressing towards the submission of a New Drug Application for D-PLEX???, its lead product candidate aimed at preventing colorectal surgical site infections. Strong results from Phase III trials have set the stage for this exciting next step in 2026. Additionally, the company's robust pipeline spans various therapeutic areas, including oncology, obesity, and diabetes.
Meeting Key Stakeholders
Attending this conference not only signifies PolyPid's dedication to innovation but also provides an opportunity to engage with leading experts, researchers, and investors in the biopharma space. Such interactions can further enhance PolyPid’s strategic partnerships and educational outreach.
Company's Future Requests
Looking ahead, the company aims to explore further advancements in localized drug administration, which can significantly impact patient care. Dialogues established at these conferences could lead to collaborative projects that align with PolyPid's mission.
Company Contact Information
For more information about PolyPid, contact:
Ori Warshavsky
908-858-5995
IR@Polypid.com
Frequently Asked Questions
What is PolyPid Ltd. known for?
PolyPid Ltd. specializes in surgical therapeutics, focusing on local, prolonged drug delivery systems to improve surgical outcomes.
Who will present at the conference?
Dalit Hazan, Deputy CEO and EVP, will deliver a presentation on innovative drug delivery methods.
What technology does PolyPid use?
The company employs PLEX technology, integrating Polymer-Lipid Encapsulation with Active Pharmaceutical Ingredients for optimized drug delivery.
What are the future prospects for PolyPid?
PolyPid is set to submit a New Drug Application for its lead product, aiming for significant impact in preventing surgical site infections.
How can I contact PolyPid?
Interested parties can reach out via email at IR@Polypid.com for more inquiries.